The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)
Open Access
- 29 February 2004
- journal article
- abstracts
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 10, 28
- https://doi.org/10.1016/j.bbmt.2003.12.117
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: